Patents by Inventor Kazuo Kurosawa

Kazuo Kurosawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220315603
    Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and found that a pyridazinyl-thiazolecarboxamide compound has DGK ? (DGKzeta) inhibitory effect, leading to completion of the present invention. The pyridazinyl-thiazolecarboxamide compound of the present invention has DGK ? inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer having resistance to anti-PD-1 antibody/anti-PD-L1 antibody therapy.
    Type: Application
    Filed: December 24, 2020
    Publication date: October 6, 2022
    Inventors: Hideyuki Watanabe, Yohei Seki, Keiichiro Okuyama, Kazuo Kurosawa, Osamu lkeda, Hiroshi Tomiyama, Yoshinori Iwai, Akihiko Nakamura, Kozo Miyasaka
  • Patent number: 9487491
    Abstract: Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: November 8, 2016
    Assignees: ASTELLAS PHARMA INC., KOTOBUKI PHARMACEUTICAL CO., LTD.
    Inventors: Itsuro Shimada, Kazuo Kurosawa, Takahiro Matsuya, Kazuhiko Iikubo, Yutaka Kondoh, Akio Kamikawa, Hiroshi Tomiyama, Yoshinori Iwai
  • Patent number: 9449474
    Abstract: A sales data processing device of the present invention accepts operations by an operator, opens a drawer, and is provided with a history acquisition unit, a reference information acquisition unit and an irregularity detection unit. The history acquisition unit acquires a history of operations by the operator. The reference information acquisition unit acquires, from references of standard operations set in advance for each of operations that cause the drawer to open, the standard operation references for operations specified in the history. For each of the operations specified in the history, the irregularity detection unit finds a difference from the standard operation reference acquired by the reference information acquisition unit, and if the difference is of at least a predetermined level, detects that the operation is an irregular drawer operation.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: September 20, 2016
    Assignee: CASIO COMPUTER CO., LTD.
    Inventor: Kazuo Kurosawa
  • Patent number: 8969336
    Abstract: Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: March 3, 2015
    Assignees: Astellas Pharma Inc., Kotobuki Pharmaceutical Co., Ltd.
    Inventors: Itsuro Shimada, Kazuo Kurosawa, Takahiro Matsuya, Kazuhiko Iikubo, Yutaka Kondoh, Akio Kamikawa, Hiroshi Tomiyama, Yoshinori Iwai
  • Publication number: 20140371196
    Abstract: Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Applicants: ASTELLAS PHARMA INC., KOTOBUKI PHARMACEUTICAL CO., LTD.
    Inventors: Itsuro SHIMADA, Kazuo KUROSAWA, Takahiro MATSUYA, Kazuhiko IIKUBO, Yutaka KONDOH, Akio KAMIKAWA, Hiroshi TOMIYAMA, Yoshinori IWAI
  • Publication number: 20130096100
    Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 18, 2013
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Yutaka KONDOH, Kazuhiko Iikubo, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani, Itsuro Shimada, Takahiro Matsuya, Kazuo Kurosawa, Akio Kamikawa, Hiroyuki Mano
  • Publication number: 20130054392
    Abstract: A sales data processing device of the present invention accepts operations by an operator, opens a drawer, and is provided with a history acquisition unit, a reference information acquisition unit and an irregularity detection unit. The history acquisition unit acquires a history of operations by the operator. The reference information acquisition unit acquires, from references of standard operations set in advance for each of operations that cause the drawer to open, the standard operation references for operations specified in the history. For each of the operations specified in the history, the irregularity detection unit finds a difference from the standard operation reference acquired by the reference information acquisition unit, and if the difference is of at least a predetermined level, detects that the operation is an irregular drawer operation.
    Type: Application
    Filed: August 8, 2012
    Publication date: February 28, 2013
    Applicant: CASIO COMPUTER CO., LTD.
    Inventor: Kazuo Kurosawa
  • Patent number: 8318702
    Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: November 27, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Yutaka Kondoh, Kazuhiko Iikubo, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani, Itsuro Shimada, Takahiro Matsuya, Kazuo Kurosawa, Akio Kamikawa, Hiroyuki Mano
  • Publication number: 20120040968
    Abstract: Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
    Type: Application
    Filed: May 6, 2010
    Publication date: February 16, 2012
    Applicant: Waters Technologies Corporation
    Inventors: Itsuro Shimada, Kazuo Kurosawa, Takahiro Matsuya, Kazuhiko Iikubo, Yutaka Kondoh, Akio Kamikawa, Hiroshi Tomiyama, Yoshinori Iwai
  • Publication number: 20100099658
    Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.
    Type: Application
    Filed: July 4, 2008
    Publication date: April 22, 2010
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Yutaka Kondoh, Kazuhiko Iikubo, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani, Itsuro Shimada, Takahiro Matsuya, Kazuo Kurosawa, Akio Kamikawa, Hiroyuki Mano
  • Publication number: 20090082367
    Abstract: [Problem] To provide a compound which may be used in treating diseases in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11?-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.
    Type: Application
    Filed: March 14, 2007
    Publication date: March 26, 2009
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Seiji Yoshimura, Ryota Shiraki, Tomoaki Kawano, Daisuke Sasuga, Mitsuru Hosaka, Hiroki Fukudome, Kazuo Kurosawa, Hirofumi Ishii, Takanori Koike
  • Patent number: 7093137
    Abstract: In a database, a frequently retrieved column is encrypted using a common key, and other columns are encrypted using a specific row key. Thus, a retrieving process can be performed at a high speed, and the security can be improved. Then, the row and column of the database are encrypted by assuming the plaintext to be encrypted as a bit string, and performing a binary operation with a random bit string. A random bit string is obtained by sequentially generating multidimensional vectors using a nonlinear function by defining a predetermined bit length as 1 word and a plurality of words as components of the multidimensional vector.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: August 15, 2006
    Assignee: Casio Computer Co., Ltd.
    Inventors: Makoto Sato, Tsuneharu Takeda, Junji Mori, Kazuo Kurosawa
  • Publication number: 20060136278
    Abstract: A headquarters manager's terminal is used to prepare work instruction information and to transfer the prepared information to a headquarters server, and the headquarters server sends the work instruction information to a mobile terminal through a store server. The mobile terminal is used to prepare work report information for reporting activities performed in accordance with the work instruction, and to send the headquarters server the work report information with a photographed image of work site attached to. The headquarter server arranges and stores the work instruction information and work report information accompanying the photographed image, both being associated with each other, in a work instruction information file. The headquarter manager's terminal reads out the work instruction information file to display the work report information associated with the work instruction information.
    Type: Application
    Filed: December 19, 2005
    Publication date: June 22, 2006
    Applicant: Casio Computer Co., Ltd.
    Inventors: Motoi Otsuka, Kazuo Kurosawa
  • Patent number: 5542518
    Abstract: A method of identifying the denominations of pieces of paper, for example, bills or securities.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: August 6, 1996
    Assignee: Toyo Communication Equipment Co., Ltd.
    Inventors: Kazuo Kurosawa, Kazuto Matsuo, Akira Minoguchi